8 ANNEX VIII COMMON SPECIFICATIONS FOR DEVICES INTENDED FOR DETECTION OF MARKERS OF VARIANT CREUTZFELDT-JACOB (vCJD) DISEASE, Regulation (EU) 2022/1107

In forcesince 4 Jul 2022

This Annex applies to devices intended for detection of markers of variant Creutzfeldt-Jakob disease (vCJD).

Table 1 applies to devices intended for detection of markers of vCJD.

Performance characteristic | Material | Number of specimens | Acceptance criteria

Analytical sensitivity | vCJD brain spikes in human plasma (WHO reference number NHBY0/0003) | ≥24 replicates of each of three dilutions of the material WHO number NHBY0/0003 (1×104, 1×105, 1×106) | 23 of the 24 replicates detected at 1×104

vCJD spleen spikes in human plasma (10% spleen homogenate — NIBSC reference number NHSY0/0009) | ≥24 replicates of each of three dilutions of the material NIBSC number NHSY0/0009 (1×10, 1×102 , 1×103 ) | 23 of the 24 replicates detected at 1×10

Diagnostic sensitivity | Specimens from appropriate animal models | As many specimens as reasonably possible and available, and ≥10 specimens | 90%

Specimens from humans with known clinical vCJD | As many specimens as reasonably possible and available, and ≥10 specimens | 90%

Only in cases where 10 specimens are not available:

the number of specimens tested shall be between 6 and 9

all available specimens shall be tested

max. one false negative result

Analytical specificity | Potentially cross-reacting specimens | ≥100 |

Diagnostic specificity | Normal human plasma specimens from area of low bovine spongiform encephalopathy (BSE) exposure | ≥5000 | ≥ 99,5 %